Analysts await Epizyme, Inc. (NASDAQ:EPZM) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.47 EPS, up 272.34% or $1.28 from last year’s $-1.75 per share.

At the moment 9 analysts are watching Epizyme, Inc. (NASDAQ:EPZM), 3 rate it “Buy”, 6 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 8 analysts have a mean sales target of 1.00 million. For the quarter ending Sep-16, 8 analysts have a mean sales target of 0.97 million whilst for the year ending Dec-16, 7 analysts have a mean target of 3.92 million.

In terms of earnings per share, 9 analysts have a -0.60 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 9 analysts have a -0.66 EPS mean target and for the quarter ending Sep-16 there are 9 estimates of -2.54 EPS.

The biggest institutional shareholders in Epizyme, Inc. include NEA 13 GP, Ltd which owns 6 million shares in the company valued at $100.30 million. Fidelity Management and Research Company is the second biggest holder with 6 million shares currently valued at 99.03 million whilst PRIMECAP Management Company has 5 million shares valued at 84.04 million.

Total shares held by institutions as of the most recent company filings are 47,723,925 with a reported 3,644,126 bought and 3,422,469 sold. These holdings make up 83.43% of the company’s outstanding shares.

Currently insiders hold 174,865 shares in the business which makes up 0.31% of shares. The biggest holder currently is Mr. Jason P. Rhodes who owns 138,000 shares (0.24% of those outstanding), whilst Mr. Andrew E. Singer holds 20,253 (0.04% of shares outstanding) and Mr. Stephen Garbacz holds 13,073 (0.02% of shares outstanding).

The stock increased 2.87% or $0.26 during the last trading session.